ReviewInflammation research : official journal of the European Histamine Research Society ... [et al.]2025
Aquaporins: a novel perspective in the treatment of lung diseases.
Review in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Multifunctional Roles of Aquaporins in Tumors: Focusing on Metabolism, Migration, and Regulation of the Tumor Microenvironment.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundAquaporins (AQPs) are a class of channel proteins expressed on the cell membrane, responsible for facilitating the transport of water molecules and certain small solutes across the membrane. Their dysregulation is involved in the occurrence and progression of major lung diseases.
findingsWe systematically reviewed the expression and functional alterations of AQPs in acute lung injury (ALI), pneumonia, asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis (PF) and lung cancer, and integrated the potential molecular mechanisms. In addition, we examine the regulatory mechanisms of traditional Chinese medicine on lung AQPs, and summarizes the research progress of inhibitors and small molecular compounds that modulate AQPs in lung diseases. IMPLICATIONS: AQPs may serve as promising therapeutic targets for lung diseases. This review offers novel insights and a foundation for the diagnosis, treatment, and drug development of lung diseases, positioning AQPs as a potential tool in combating these conditions.
Indexed as
Identifiers
41144048What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.